Durability of clinical benefit and biomarkers in patients (pts) with advanced non-small cell lung cancer (NSCLC) treated with AMG 510 (sotorasib)

被引：6
|
作者：
Hong, D. S. [1 ]
Bang, Y-J. [2 ]
Barlesi, F. [3 ]
Durm, G. A. [4 ]
Falchook, G. S. [5 ]
Govindan, R. [6 ]
Dy, G. K. [7 ]
Park, K. [8 ]
Strickler, J. H. [9 ]
Burns, T. F. [10 ]
Kim, J. [11 ]
Ang, A. [12 ]
Lipford, J. R. [13 ]
Ngarmchamnanrith, G.
Anderson, A. [12 ]
Li, B. T. [14 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Phase & Clin Trials Program, Dept Invest Canc Therapeut, Houston, TX 77030 USA
[2] Seoul Natl Univ, Coll Med, Dept Internal Med Med Oncol, Seoul, South Korea
[3] Aix Marseille Univ, CNRS, INSERM, CRCM,AP HP, Gustave Roussy Canc Campus, Villejuif, France
[4] Indiana Univ, Sch Med, Dept Med, Div Hematol Oncol, Indianapolis, IN USA
[5] HealthONE, Sarah Cannon Res Inst, Dept Med Oncol, Denver, CO USA
[6] Washington Univ, Sch Med, Alvin J Siteman Canc Ctr, St Louis, MO USA
[7] Roswell Pk Comprehens Canc Ctr, Dept Med, Buffalo, NY USA
[8] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea
[9] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA
[10] Univ Pittsburgh, Med Ctr, Hillman Canc Ctr, Dept Med,Div Hematol Oncol, Pittsburgh, PA USA
[11] Amgen Inc, Biostat, Thousand Oaks, CA 91320 USA
[12] Amgen Inc, Oncol Res, Thousand Oaks, CA 91320 USA
[13] Amgen Inc, Clin Dev, Thousand Oaks, CA 91320 USA
[14] Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.08.1571
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1257O
引用
收藏
页码：S812 / S812
页数：1
相关论文
共 50 条
  • [1] Durability of clinical benefit and biomarkers in patients (pts) with advanced non-small cell lung cancer (NSCLC) treated with AMG 510 (sotorasib)
    Hong, D. S.
    Bang, Y-J.
    Barlesi, F.
    Durm, G.
    Falchook, G. S.
    Govindan, R.
    Dy, G. K.
    Park, K.
    Strickler, J. H.
    Burns, T. F.
    Kim, J.
    Ang, A.
    Lipford, J. R.
    Ngarmchamnanrith, G.
    Anderson, A.
    Li, B. T.
    ANNALS OF ONCOLOGY, 2020, 31 : S1389 - S1390
  • [2] Durability of Clinical Benefit and Biomarkers in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Treated with Sotorasib, a KRAS(G12C) Inhibitor
    Hong, D. S.
    Bang, Y. -J.
    Barlesi, F.
    Durm, G.
    Falchook, G.
    Govindan, R.
    Dy, G.
    Park, K.
    Strickler, J.
    Burns, T.
    Kim, J.
    Ang, A.
    Lipford, J. R.
    Ngarmchamnanrith, G.
    Anderson, A.
    Li, B. T.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S28 - S29
  • [3] Spotlight on Sotorasib (AMG 510) for KRASG12C Positive Non-Small Cell Lung Cancer
    Zhang, Shannon S.
    Nagasaka, Misako
    LUNG CANCER-TARGETS AND THERAPY, 2021, 12 : 115 - 122
  • [4] Trends in demographics and survival for patients (pts) with advanced non-small cell lung cancer (NSCLC).
    Kubota, K.
    Masuhara, H.
    Hosoya, K.
    Yoh, K.
    Niho, S.
    Goto, K.
    Ohmatsu, H.
    Nishiwaki, Y.
    Saijo, N.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 392S - 392S
  • [5] Benefit of immunotherapy (IT) in advanced non-small cell lung cancer (NSCLC) in elderly patients (EP)
    Corral de la Fuente, E.
    Barquin Garcia, A.
    Saavedra Serrano, C.
    Olmedo Garcia, M. E.
    Martin Huertas, R.
    Serrano Domingo, J. J.
    Albarr Anartahona, V.
    Gomez Rueda, A.
    ANNALS OF ONCOLOGY, 2019, 30
  • [6] Cobolimab With Dostarlimab and Docetaxel in Patients (pts) With Advanced Non-small Cell Lung Cancer (NSCLC): COSTAR Lung
    Kim, Hye Ryun
    Gridelli, Cesare
    Kapur, Dinesh
    Tufman, Amanda
    Felip, Enriqueta
    Velcheti, Vamsidhar
    Kim, Yu Jung
    Goetze, Thorsten
    Lopez, Pilar Garrido
    Corre, Romain
    Penkov, Konstantin
    Anjum, Rana
    Di Pace, Brian
    Liu, Wenlei
    Borgovan, Theo
    Ledger, Danielle
    Carver, Jennifer
    Waszak, Angela
    Dhar, Arindam
    Novello, Silvia
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 163 - 163
  • [7] The association between PTEN expression and survival in patients (pts) with advanced non-small cell lung cancer (NSCLC) treated with erlotinib
    Hensing, T. A.
    Fidler, M. J.
    Wong, F.
    Polish, A.
    Watkin, W.
    Basu, S.
    Kaiser-Walters, K. A.
    Pool, M.
    Coon, J.
    Bonomi, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [8] Predictive value of KRAS mutations in advanced non-small cell lung cancer (NSCLC) patients (pts) treated with chemotherapy (CT)
    Dingemans, Anne-Marie C.
    Smit, Egbert F.
    Derks, Jules
    Mellema, Wouter
    Heideman, Danielle
    Van Suylen, Robertjan
    Thunnissen, Erik
    CANCER RESEARCH, 2011, 71
  • [9] Safety and efficacy of dostarlimab in patients (pts) with recurrent/advanced non-small cell lung cancer (NSCLC)
    Subramanian, J.
    Moreno, V.
    Bosch-Barrera, J.
    Pikiel, J.
    Kristeleit, R.
    Guo, W.
    Danaee, H.
    Im, E.
    Roda, D.
    ANNALS OF ONCOLOGY, 2020, 31 : S886 - S887
  • [10] Tepotinib in patients (pts) with advanced non-small cell lung cancer (NSCLC) with MET amplification (METamp).
    Le, Xiuning
    Paz-Ares, Luis G.
    Van Meerbeeck, Jan
    Viteri, Santiago
    Galvez, Carlos Cabrera
    Baz, David Vicente
    Kim, Young-Chul
    Kang, Jin-Hyoung
    Schumacher, Karl-Maria
    Karachaliou, Niki
    Adrian, Svenja
    Bruns, Rolf
    Paik, Paul K.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345